Mangoceuticals, Inc.
MGRX- Exchange
- Nasdaq
- Industry
- Services-Misc Health & Allied Services, NEC
- SEC CIK
- 0001938046
No open-market purchases or sales by Mangoceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $455.6K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Mangoceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +1 vs. Q1 2026
- Shares held
- 1.20M
- +386.3K (+47.4%) vs. Q1 2026
- Total value
- $455.6K
- +$162.3K (+55.3%) vs. Q1 2026
- New holders
- 5
- 1 more added
- Sold out
- 4
- 3 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MGRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $455.6K |
| Q1 2026 | 18 | $297.6K |
| Q4 2025 | 18 | $1.88M |
| Q3 2025 | 11 | $820.1K |
| Q2 2025 | 10 | $444.2K |
| Q1 2025 | 8 | $146.9K |
| Q4 2024 | 9 | $220.9K |
| Q3 2024 | 13 | $319.7K |
| Q2 2024 | 6 | $147.7K |
| Q1 2024 | 8 | $76.5K |
| Q4 2023 | 5 | $34.9K |
| Q3 2023 | 9 | $135.8K |
| Q2 2023 | 5 | $166.4K |
| Q1 2023 | 1 | $5.32K |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Mangoceuticals, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 338,964 | $128.8K | 0.00% | +338,964 | New |
| XTX Topco Ltd | 186,256 | $70.8K | 0.00% | +173,114+1,317.3% | Added |
| Geode Capital Management, LLC | 156,243 | $59.4K | 0.00% | −38,239−19.7% | Reduced |
| Ikarian Capital, LLC | 138,146 | $52.5K | 0.01% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 123,041 | $46.8K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 57,163 | $21.7K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 38,441 | $14.6K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 37,579 | $14.3K | 0.00% | 00.0% | Unchanged |
| Ackerman Capital Advisors, LLC | 34,500 | $13.1K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 36,003 | $13.0K | 0.00% | +36,003 | New |
| ACT Advisors, LLC. | 26,863 | $10.2K | 0.00% | +26,863 | New |
| Goldman Sachs Group Inc | 11,589 | $4.40K | 0.00% | −168−1.4% | Reduced |
| Csenge Advisory Group | 10,000 | $3.80K | 0.00% | 00.0% | Unchanged |
| Ameriflex Group, Inc. | 2,885 | $1.10K | 0.00% | +2,885 | New |
| Fortitude Family Office, LLC | 1,343 | $510 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,000 | $380 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 783 | $298 | 0.00% | −2−0.3% | Reduced |
| Barclays PLC | 5 | $2 | 0.00% | +5 | New |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −72,746−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −61,028−100.0% | Sold out |
| StoneX Group Inc. | 0 | $0 | 0.00% | −16,039−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −3,285−100.0% | Sold out |
| Sunbelt Securities, Inc. | – | – | – | – | Not filed |